We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
1 Notice of final decisions to amend (or not amend) the current Poisons Standard
This web publication constitutes a notice for the purposes of regulation 42ZCZS and regulation 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes the:
- decisions made by a delegate of the Secretary pursuant to regulations 42ZCZR and 42ZCZU;
- reasons for those final decisions; and
- date of effect of those decisions.
2 Final decision in relation to psilocybin and MDMA [N, α-Dimethyl-3,4-(methylenedioxy)phenylethylamine]
Note that the final decision for psilocybin and MDMA [N, α-Dimethyl-3,4-(methylenedioxy)phenylethylamine] are not published in this notice.
Amended timing on the scheduling process for these substances will be published on the TGA website following the completion of the independent review.
3 Final decision in relation to bilastine - correction
Note that the final decision on bilastine inadvertently omitted the amendment to include the substance in the list of non-sedating antihistamines in Appendix F, Part 3, as requested by the applicant. A delegate-only decision has been made to correct this and the amendment will be included in the June 2021 version of the Poisons Standard.
Final decisions and reasons
- Notice of final decisions - ACMS #32, ACCS #29, Joint ACMS-ACCS #26, November 2020 meetings (pdf,376kb)
- Notice of final decisions - ACMS #32, ACCS #29, Joint ACMS-ACCS #26, November 2020 meetings (docx,106kb)
We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au (for substances referred to the ACMS or Joint ACCS-ACMS) or chemicals.scheduling@health.gov.au (for substances referred to the ACCS).
Contents
- 1 Notice of final decisions to amend (or not amend) the current Poisons Standard
- 2 Final decision in relation to psilocybin and MDMA [N, α-Dimethyl-3,4-(methylenedioxy)phenylethylamine]
- 3 Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #32, November 2020)
- 3.1 Final decision in relation to amygdalin and hydrocyanic acid
- 3.2 Final decision in relation to bilastine
- 3.3 Final decision in relation to budesonide and formoterol
- 4 Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #29, November 2020)
- 4.1 Final decision in relation to azoxystrobin
- 4.2 Final decision in relation to triticonazole
- 5 Final decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACMS-ACCS #26, November 2020)
- 5.1 Final decision in relation to azelaic acid
- 5.2 Final decision in relation to 2-hydroxyethyl methacrylate (2-HEMA)
- 5.3 Final decision in relation to magnesium hydroxide
- 5.4 Final decision in relation to tetrahydrofurfuryl alcohol
- 5.5 Final decision in relation to cannabidiol (private application)